Incyte Says It's No Longer A One-Drug Story
Incyte Corp. (NASDAQ: INCY ) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opzelura and its hematology and oncology products. The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion. Total net sales increased 40% to $1.49 billion. Excluding a one-time, non-cash benefit tied to a Centers for Medicare & Medicaid Services (CMS) settlement related to Opzelura, net sales grew 17%. “Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,” Chief Executive Officer Bill Meury said. Incyte used its second-quarter...
Incyte Corp. (NASDAQ: INCY ) reported better-than-expected second-quarter results on Tuesday and raised its full-year sales guidance after broad-based growth across its commercial portfolio, led by strong demand for Opzelura and its hematology and oncology products. 12. 46 billion.
49 billion. Excluding a one-time, non-cash benefit tied to a Centers for Medicare & Medicaid Services (CMS) settlement related to Opzelura, net sales grew 17%. “Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,” Chief Executive Officer Bill Meury said. Incyte used its second-quarter earnings call to argue that it is evolving beyond its longtime dependence on Jakafi.
Meury said the company now has multiple growth drivers, pointing to broad-based commercial sales growth, several near-term product launches, a maturing late-stage pipeline and the recently acquired Vega Therapeutics asset. He said Incyte is “no longer dependent on one asset, catalyst or blockbuster,” with its business increasingly supported by multiple products and pipeline opportunities. Opzelura, Jakafi Drive Sales Growth Jakafi and Jakafi XR generated net sales of $817 million, up 7% from a year earlier. Opzelura net sales surged 173% to $450 million, aided by a $246 million one-time accounting benefit from the CMS settlement.
Excluding that benefit, Opzelura sales increased 24% to $204 million. The company’s hematology and oncology portfolio delivered net sales of $222 million, up 69%, driven by continued growth for Niktimvo, Monjuvi/Minjuvi and Zynyz. 94 billion. 712 billion.
10 billion from $750 million-$790 million. It also raised its hematology and oncology portfolio sales outlook to $860 million-$890 million from $800 million-$880 million. 27 billion. The company also raised its operating expense guidance following the acquisition of Vega Therapeutics.
27 billion in the third quarter. It also includes about $50 million in additional research investments related to latarcibart. Pipeline And Balance Sheet Incyte said it expects 10 clinical data readouts, including results from four registrational trials, during the second half of 2026. The company also completed the acquisition of Vega Therapeutics, adding Phase 3 asset latarcibart for von Willebrand disease to its pipeline.
6 billion at the end of 2025. 40 at the time of publication on Tuesday. The stock is trading at a new 52-week high, according to Pro data. Photo via Shutterstock Read Also: SpaceX Wipes Out a Full Tesla's Worth of Market Value Since Peaking in June